DelveInsight’s “HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Insight 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline landscape. It covers the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline? @ https://www.delveinsight.com/sample-request/hpv-recurrentmetastatic-head-and-neck-cancer-pipeline-insight

Key Takeaways from the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report

• On April 09, 2026- GlaxoSmithKline conducted a phase 2 study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
• On April 06, 2026- PDS Biotechnology Corp. initiated a Phase 3 study that is randomized 1:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherapy as first-line treatment in patients with unresectable recurrent or metastatic HPV16-positive HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1.
• On April 06, 2026- AVEO Pharmaceuticals Inc. announced a phase 3 study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
• DelveInsight’s HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for HPV+ Recurrent/Metastatic Head and Neck Cancer treatment.
• The leading HPV+ Recurrent/Metastatic Head and Neck Cancer Companies such as BioNTech, Cue Biopharma, Hookipa Pharma and others.
• Promising HPV+ Recurrent/Metastatic Head and Neck Cancer Therapies such as PF-00299804, GSK1363089 (foretinib), Pemetrexed, Cetuximab, Cisplatin, Carboplatin, RiMO-301 and others.

Want to know which companies are leading innovation in HPV+ Recurrent/Metastatic Head and Neck Cancer? @ HPV+ Recurrent/Metastatic Head and Neck Cancer Clinical Trials Assessment

The HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report also highlights the unmet needs with respect to the HPV+ Recurrent/Metastatic Head and Neck Cancer.

HPV+ Recurrent/Metastatic Head and Neck Cancer Overview

Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box). These cancers are referred to as squamous cell carcinomas of the head and neck. Head and neck cancers can also begin in the salivary glands, sinuses, or muscles or nerves in the head and neck, but these types of cancer are much less common than squamous cell carcinomas. Head and neck cancer symptoms may include a lump in the neck or a sore in the mouth or the throat that does not heal and may be painful, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice.

HPV+ Recurrent/Metastatic Head and Neck Cancer Emerging Drugs Profile

• CUE 101: Cue Biopharma

Cue Biopharma is advancing a pipeline of targeted interleukin 2 (IL-2)-based immunotherapies for multiple types of cancers with high unmet needs. The CUE-100 series of biologics have the potential to improve efficacy and reduce the severe toxicities associated with non-specific IL-2 cancer immunotherapies. CUE-101, has already demonstrated clinical activity and favorable tolerability as a monotherapy in a Phase 1 trial in patients with human papilloma virus (HPV16+) recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

• BNT 113: BioNTech

BNT113 is an mRNA cancer vaccine encoding two oncoproteins, E6 and E7,that are frequently found in HPV16+ solid cancers aiming to trigger a strong and precise immune response in patients with HPV16+ head and neck squamous cell carcinoma (HNSCC). BNT113 is currently being evaluated in a Phase 2 study, AHEAD-MERIT, in combination with Merck’s pembrolizumab, a PD-1 inhibitor, vs. pembrolizumab alone in patients with unresectable recurrent or metastatic HPV+ PD-1+ HNSCCs. Results from an investigator-initiated Phase 1/2 basket trial, HARE-40, in patients with HPV16+ cancers showed that BNT113 treatment induces potent, antigen-specific T cell responses.

If you’re tracking ongoing HPV+ Recurrent/Metastatic Head and Neck Cancer Clinical trials @ HPV+ Recurrent/Metastatic Head and Neck Cancer Treatment Drugs

The HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of HPV+ Recurrent/Metastatic Head and Neck Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HPV+ Recurrent/Metastatic Head and Neck Cancer Treatment.
• HPV+ Recurrent/Metastatic Head and Neck Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HPV+ Recurrent/Metastatic Head and Neck Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HPV+ Recurrent/Metastatic Head and Neck Cancer market.

HPV+ Recurrent/Metastatic Head and Neck Cancer Companies

BioNTech, Cue Biopharma, Hookipa Pharma and others.

HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

HPV+ Recurrent/Metastatic Head and Neck Cancer Products have been categorized under various Molecule types such as,

• Oligonucleotide
• Peptide
• Small molecule

From emerging drug candidates to competitive intelligence, the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report @ HPV+ Recurrent/Metastatic Head and Neck Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Report

• Coverage- Global
• HPV+ Recurrent/Metastatic Head and Neck Cancer Companies- BioNTech, Cue Biopharma, Hookipa Pharma and others.
• HPV+ Recurrent/Metastatic Head and Neck Cancer Therapies- PF-00299804, GSK1363089 (foretinib), Pemetrexed, Cetuximab, Cisplatin, Carboplatin, RiMO-301 and others.
• HPV+ Recurrent/Metastatic Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• HPV+ Recurrent/Metastatic Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the HPV+ Recurrent/Metastatic Head and Neck Cancer Treatment landscape in this detailed analysis @ HPV+ Recurrent/Metastatic Head and Neck Cancer Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. HPV+ Recurrent/Metastatic Head and Neck Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. HPV+ Recurrent/Metastatic Head and Neck Cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mid Stage Products (Phase II)
9. Early Stage Products (Phase I)
10. BNT 113: BioNTech
11. Preclinical and Discovery Stage Products
12. Inactive Products
13. HPV+ Recurrent/Metastatic Head and Neck Cancer Key Companies
14. HPV+ Recurrent/Metastatic Head and Neck Cancer Key Products
15. HPV+ Recurrent/Metastatic Head and Neck Cancer- Unmet Needs
16. HPV+ Recurrent/Metastatic Head and Neck Cancer- Market Drivers and Barriers
17. HPV+ Recurrent/Metastatic Head and Neck Cancer- Future Perspectives and Conclusion
18. HPV+ Recurrent/Metastatic Head and Neck Cancer Analyst Views
19. HPV+ Recurrent/Metastatic Head and Neck Cancer Key Companies
20. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/hpv-recurrentmetastatic-head-and-neck-cancer-pipeline-insight